STADA ARZNEIMITT. NA O.N. news, videos and press releases
For more news please use our advanced search feature.
STADA ARZNEIMITT. NA O.N. - More news...
STADA ARZNEIMITT. NA O.N. - More news...
- DGAP-News: STADA Arzneimittel Aktiengesellschaft Announcement of the Results of the Tender Offer
- DGAP-News: Upcoming Expiration of Tender Offer and Intention to Delist Notes
- DGAP-News: STADA Arzneimittel Aktiengesellschaft Announcement of the Results of the Tender Offer
- DGAP-News: STADA Arzneimittel Aktiengesellschaft Announcement of the Results of the Tender Offer
- DGAP-News: STADA Arzneimittel AG: Announcement of the Results of the Tender Offer
- DGAP-News: STADA Arzneimittel Aktiengesellschaft Announcement of the Results of the Tender Offer
- DGAP-News: STADA Arzneimittel Aktiengesellschaft Announcement of the Results of the Tender Offer
- DGAP-News: STADA's EUR 300,000,000 1.75% Senior Notes due 2022
- DGAP-News: STADA Arzneimittel AG: STADA: Completion of the compliance investigation
- DGAP-Adhoc: STADA's EUR300,000,000 1.75% Senior Notes due 2022: announcement of an instruction to grant in rem securities
-
DGAP-WpÜG: Tender Offer;
- DGAP-News: STADA Arzneimittel AG: Voting results of the bondholders' meeting concerning the STADA-Bond 2015/2022
- DGAP-News: STADA Arzneimittel AG: STADA invites the holders of the STADA Bond to participate in the bondholders' meeting and to vote in favor of the proposed resolutions
- DGAP-News: STADA Arzneimittel AG: Peter Goldschmidt to succeed Claudio Albrecht as STADA's CEO
- DGAP-News: STADA Arzneimittel AG: STADA's business development in the first six months of 2018 as expected
- DGAP-News: STADA Arzneimittel AG: STADA becomes Majority Shareholder of BIOCEUTICALS Arzneimittel AG
- DGAP-News: STADA Arzneimittel AG: STADA Repurchases Rights for Ladival
- DGAP-News: STADA Arzneimittel AG: Voting results of the bondholders' meeting on July 17, 2018 concerning the STADA-Bond 2015/2022: Appointment of One Square Advisory Services GmbH as joint representative and adjournment of the further agenda items
- DGAP-News: STADA Arzneimittel AG: Xbrane and STADA enter into a co-development agreement for Xlucane
- DGAP-News: STADA Arzneimittel AG: Announcement of the results of the Tender Offer regarding the STADA-Bond 2015/2022:
- DGAP-News: STADA Arzneimittel AG: NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO OR TO ANY PERSON LOCATED IN THE UNITED STATES.
- DGAP-News: STADA Arzneimittel AG: Strategic expansion of OTC portfolio continues - STADA acquires EMEA rights to global anti-dandruff brand Nizoral from Janssen Pharmaceutica
- DGAP-News: STADA Arzneimittel AG: Consent Solicitation for STADA Euro bond 2015/2022
- DGAP-News: STADA Arzneimittel AG: Annual General Meeting approves agenda items with a large majority
- DGAP-News: STADA Arzneimittel AG: STADA with solid business development in the first quarter of 2018
- DGAP-News: STADA Arzneimittel AG: Changes in the management team of STADA
- DGAP-Adhoc: STADA Arzneimittel AG: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange
- DGAP-News: STADA Arzneimittel AG: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of acceptance period for severance offer
- DGAP-News: STADA records positive business development in 2017
- DGAP-Adhoc: STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of EUR0.11 per share
